Linked Life Data

20656010

Source:http://linkedlifedata.com/resource/pubmed/id/20656010

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-8-31
pubmed:abstractText
Berberine, a natural product, has been widely used to treat hyperlipoidemia and intestinal diseases. In the present paper, berberine showed a significant anti-proliferative effect to human cervical carcinoma HeLa cells confirmed by 3-(4,5)-dimethyl-thiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide (MTT), flow cytometry analysis (FCM) and so on. The methods including western blotting, radioimmunity assay (RIA), reverse transcription-polymerase chain reaction (RT-PCR) were used to investigate protein and mRNA expressions. We found that Bcl-2/Bax ratio was significantly decreased and cytochrome c was released from mitochondrion to cytosol, which indicated that the mitochondrial pathway was activated by berberine. The up-regulation of Fas, FasL, TNF-alpha and TRAF-1 indicated the involvement of the death receptor pathway in the process of berberine-induced apoptosis. Furthermore caspase-3 and caspase-8 were activated as a central event of apoptosis, and the levels of phosphorylation of mitogen-activated protein kinases (MAPKs) were also investigated. In addition, the increased expression of p53 was also observed in berberine-treated HeLa cells, and as a node point of these different pathways in a protein-protein interaction network constructed by GeneGo software, p53 might be the possible drug-target of berberine's anti-cancer on HeLa cells, which was predicted by a flexible ligand-protein inverse docking program, INVDOCK. This study is benefit for clarifying the mechanism of berberine's anti-tumor effect and might be helpful to find therapy-target for treatment of human cervical carcinoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1879-3177
pubmed:author
pubmed:copyrightInfo
Copyright 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1482-90
pubmed:meshHeading
pubmed-meshheading:20656010-Antigens, CD95, pubmed-meshheading:20656010-Antineoplastic Agents, pubmed-meshheading:20656010-Apoptosis, pubmed-meshheading:20656010-Berberine, pubmed-meshheading:20656010-Cell Survival, pubmed-meshheading:20656010-Computational Biology, pubmed-meshheading:20656010-Drug Discovery, pubmed-meshheading:20656010-Fas Ligand Protein, pubmed-meshheading:20656010-Female, pubmed-meshheading:20656010-Gene Expression, pubmed-meshheading:20656010-HeLa Cells, pubmed-meshheading:20656010-Humans, pubmed-meshheading:20656010-Mitochondria, pubmed-meshheading:20656010-Mitogen-Activated Protein Kinase Kinases, pubmed-meshheading:20656010-RNA, Messenger, pubmed-meshheading:20656010-Receptors, Death Domain, pubmed-meshheading:20656010-TNF Receptor-Associated Factor 1, pubmed-meshheading:20656010-Tumor Necrosis Factor-alpha, pubmed-meshheading:20656010-Tumor Stem Cell Assay, pubmed-meshheading:20656010-Uterine Cervical Neoplasms
pubmed:year
2010
pubmed:articleTitle
Cytotoxicity of berberine on human cervical carcinoma HeLa cells through mitochondria, death receptor and MAPK pathways, and in-silico drug-target prediction.
pubmed:affiliation
College of Pharmacy, Dalian Medical University, Dalian, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't